Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928018 · ClinicalTrials.gov registry record · Phase 3
Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
A Phase 3 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 139
- Enrollment target
NCT00928018 is a Phase 3 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 139 participants.
The verdict
NCT00928018, a Phase 3 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 139 participants
- Enrollment target
Study Summary
This trial is comparing whether using a drug called sirolimus for graft versus host disease (GVHD) prevention can decrease the chance of the participant's lymphoma relapsing after transplantation, compared to using a standard GVHD prevention regimen without sirolimus. Since mTOR inhibitors have anti-lymphoma activity, their use after transplantation may lead to a decreased risk of relapse and hence better transplantation outcome.
Interventions
- DRUG Sirolimus
- DRUG Tacrolimus
- DRUG Methotrexate
- DRUG Cyclosporine
- DRUG MMF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2009-06 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00928018
The ClinicalTrials.gov registry entry for NCT00928018 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sirolimus is the first listed.
NCT00928018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00928018 about?
NCT00928018 is a clinical study titled "Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma". This trial is comparing whether using a drug called sirolimus for graft versus host disease (GVHD) prevention can decrease the chance of the participant's lymphoma relapsing after transplantation, compared to using a standard GVHD prevention regimen without sirolimus. Since mTOR inhibitors have anti...
What is the current status of trial NCT00928018?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 139 participants. The study started on 2009-06. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00928018?
The interventions under investigation include: Sirolimus (DRUG), Tacrolimus (DRUG), Methotrexate (DRUG), Cyclosporine (DRUG), MMF (DRUG).
Who is sponsoring clinical trial NCT00928018?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.